文献速递创伤与烧伤消化、代谢与肾脏急症

氯胺酮用于急性骨折镇痛:随机对照试验的系统评价与Meta分析

Ketamine for pain control in acute bone fractures: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · J Trauma Acute Care Surg · 2026-01-09
一句话结论14项RCT共1453例急性骨折患者,氯胺酮与对照在15、30、60分钟疼痛强度及追加镇痛、住院时长、满意度上无显著差异,但神经系统与精神类不良事件增加。

该系统评价与Meta分析检索PubMed、Cochrane和Embase截至2025年7月的随机对照试验,纳入14项RCT共1453例成人急性骨折患者,比较氯胺酮(单药或辅助)与安慰剂、标准治疗或其他镇痛方案。结果显示,氯胺酮组与对照组在15、30、60分钟疼痛强度上均无统计学显著差异(p>0.05),追加镇痛需求、住院时长和患者满意度也无显著差异(p>0.05)。总体不良事件相当,但氯胺酮与神经系统不良事件(48% vs 16%)和精神类不良事件(14.6% vs 4%)增加相关。排除高偏倚风险研究的敏感性分析提示15分钟时氯胺酮疗效有改善趋势(SMD -1.24;95%CI -2.72, 0.24;p=0.10),30分钟时显著改善(SMD -0.43;95%CI -0.12, 0.75;p=0.007)。

要点

  • 14项RCT共1453例成人急性骨折患者,氯胺酮与对照在15、30、60分钟疼痛强度上无统计学显著差异(p>0.05)。
  • 追加镇痛需求、住院时长和患者满意度在氯胺酮组与对照组间无显著差异(p>0.05)。
  • 氯胺酮组神经系统不良事件发生率48% vs 对照组16%,精神类不良事件14.6% vs 对照组4%。
  • 排除高偏倚风险研究的敏感性分析中,30分钟疼痛强度SMD -0.43(95%CI -0.12, 0.75;p=0.007),15分钟SMD -1.24(95%CI -2.72, 0.24;p=0.10)。
  • 作者结论:氯胺酮用于急性骨折镇痛与传统方法相比差异极小至无差异,但观察到追加镇痛(包括阿片类药物消耗)减少的趋势,神经系统和精神类不良事件增加需要严格医学监测。

适用人群与场景

  • 成人急性骨骨折患者,研究场景为急诊或急性期镇痛。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入14项随机对照试验,共1453例成人急性骨骨折患者。
  • 干预与对照:氯胺酮(单药或辅助)对比安慰剂、标准治疗或其他镇痛管理。
  • 主要终点:15、30、60分钟疼痛强度在氯胺酮组与对照组间均无统计学显著差异(p>0.05)。
  • 关键次要终点:追加镇痛需求、住院时长、患者满意度在两组间均无显著差异(p>0.05)。
  • 不良事件:总体不良事件相当,但氯胺酮组神经系统不良事件48% vs 对照组16%,精神类不良事件14.6% vs 对照组4%。
  • 敏感性分析(排除高偏倚风险研究):15分钟疼痛强度SMD -1.24(95%CI -2.72, 0.24;p=0.10),30分钟SMD -0.43(95%CI -0.12, 0.75;p=0.007)。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析;证据等级Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,氯胺酮用于急性骨骨折镇痛与传统方法相比在疼痛管理上差异极小至无差异,但注意到追加镇痛(包括阿片类药物消耗)减少的趋势。
  • 作者指出,氯胺酮相关神经系统和精神类不良事件发生率增加,需要严格医学监测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: This systematic review and meta-analysis evaluated the efficacy and safety of ketamine for pain management in acute bone fractures, assessing pain intensity, additional analgesia needs, hospital stay, patient satisfaction, and adverse events.

METHODS: A systematic search of PubMed, Cochrane, and Embase databases was conducted up to July 2025, identifying randomized controlled trials involving adult patients with acute bone fractures. Studies comparing ketamine (monotherapy or adjuvant) against placebo, standard care, or alternative pain management were included. Data extraction and risk of bias assessment were performed independently by two reviewers. Meta-analyses used random-effects models, with continuous outcomes analyzed via mean differences and standardized mean differences, and dichotomous outcomes via risk ratios.

RESULTS: Fourteen randomized controlled trials, encompassing 1,453 patients, were included. No statistically significant differences in pain intensity were found between ketamine and control groups at 15, 30, or 60 minutes (p>0.05). Similarly, no significant differences were observed in additional analgesia requirements, hospital length of stay, or patient satisfaction (p>0.05). While overall adverse events were comparable, ketamine was associated with increased rates of nervous system (48% vs 16%) and psychiatric (14,6% vs 4%) adverse events. Sensitivity analysis, excluding high-risk bias studies, suggested a trend toward improved ketamine efficacy at 15 minutes (SMD -1.24; 95% CI -2.72, 0.24; p=0.10) and significant improvement at 30 minutes (SMD -0.43; 95% CI -0.12, 0.75; p=0.007).

CONCLUSION: Ketamine for acute bone fractures shows minimal to no difference in pain management compared with conventional approaches. However, a trend toward reduced additional analgesia, including opioid consumption, was noted. The increased incidence of nervous system and psychiatric adverse events with ketamine necessitates strict medical monitoring.

LEVEL OF EVIDENCE: Systematic Review and Meta-analysis; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Lima JPC, Piredda GV, Lima EVNB, et al. Ketamine for pain control in acute bone fractures: A systematic review and meta-analysis of randomized controlled trials. J Trauma Acute Care Surg. 2026. PMID: 41632265. doi:10.1097/TA.0000000000004838

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。